Trial Profile
Personalizing enzalutamide (Xtandi®) therapy by understanding the relation between the decrease in the expression profile of a panel of preselected microRNAs, tumor related mRNAs and treatment response in patients with mCRPC (ILUMINATE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ILUMINATE
- 30 Mar 2023 Results investigated whether changes in circulating tumor DNA (ctDNA) fraction during ARPI treatment are linked with mCRPC clinical outcomes by collecting Plasma cell-free DNA from NCT02426333;NCT02471469, published in the Clinical Cancer Research
- 07 Jun 2022 Pooled results from NCT02426333 and NCT02471469 studies presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 11 Jun 2015 New trial record